Distributions of enterococci and human-specific bacteriophages of enterococci in a tropical watershed. Chyerochana N, Kongprajug A, Somnark P, Leelapanang Kamphaengthong P, Mongkolsuk S, Sirikanchana K. Int J Hyg Environ Health. 2020 May;226:113482. doi: 10.1016/j.ijheh.2020.113482. Epub 2020 Feb 19. PMID: 32087504

28 Dec 2020
0
0

Distributions of enterococci and human-specific bacteriophages of enterococci in a tropical watershed.
Chyerochana N, Kongprajug A, Somnark P, Leelapanang Kamphaengthong P, Mongkolsuk S, Sirikanchana K.
Int J Hyg Environ Health. 2020 May;226:113482. doi: 10.1016/j.ijheh.2020.113482. Epub 2020 Feb 19.
PMID: 32087504

Tags

Share this

Related Posts

Environmental pollution: An underrecognized threat to children’s health, especially in low- and middle-income countries. Suk, W. A., Ahanchian, H., Asante, K. A., Carpenter, D. O., Diaz-Barriga, F., Ha, E. H., Landrigan, P. J. (2016). Environmental Health Perspectives, 124(3), A43-A45.
01 Mar 2016
0

Environmental pollution: An underrecognized threat to children’s health, especially in low- and middle-income countries. Suk, W. A., Ahanchian, H., Asante, K. A., Carpenter, D. O., Diaz-Barriga, F., Ha, E. H., Landrigan, P. J. (2016). Environmental Health Perspectives, 124(3), A43-A45.

Environmental pollution: An underrecognized threat to children’s health, especially in low- and middle-income countries. Suk, W. A., Ahanchian, H., Asante, K. A., Carpenter, D. O., Diaz-Barriga, F., Ha, E. H., Landrigan, P. J. (2016). Environmental Health Perspectives, 124(3), A43-A45.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More